Scinovex
article Open AccessTop 1% cited

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

Journal of Clinical Oncology · 2006 · Vol. 24(31) · pp. 4991–4997
Eric Van CutsemVladimir MoiseyenkoSergei TjulandinAlejandro MajlisManuel ConstenlaC. BoniAdriano RodriguesM FodorYee ChaoЭ К ВозныйMarie-Laure RisseJaffer A. Ajani

Abstract

Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity. Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.

Gastric Cancer Management and OutcomesColorectal Cancer Treatments and StudiesCholangiocarcinoma and Gallbladder Cancer StudiesDocetaxelMedicineFluorouracilNeutropeniaInternal medicineCisplatinGastroenterologyRegimenPhases of clinical researchChemotherapy

MeSH terms

DocetaxelAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinDrug Administration ScheduleFemaleFluorouracilHumansMaleMiddle AgedQuality of LifeStomach NeoplasmsSurvival Analysis

Funding

  • Sanofi
Citations
1,929
FWCI
66.49
field-weighted impact
References
32
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.